KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Raw Materials: 2010-2020

Historic Raw Materials for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Dec 2020 value amounting to $76.7 million.

  • Biomarin Pharmaceutical's Raw Materials rose 1.99% to $75.3 million in Q3 2021 from the same period last year, while for Sep 2021 it was $75.3 million, marking a year-over-year increase of 1.99%. This contributed to the annual value of $76.7 million for FY2020, which is 3.00% up from last year.
  • As of FY2020, Biomarin Pharmaceutical's Raw Materials stood at $76.7 million, which was up 3.00% from $74.4 million recorded in FY2019.
  • Biomarin Pharmaceutical's Raw Materials' 5-year high stood at $76.7 million during FY2020, with a 5-year trough of $49.9 million in FY2017.
  • Over the past 3 years, Biomarin Pharmaceutical's median Raw Materials value was $74.6 million (recorded in 2018), while the average stood at $75.2 million.
  • Its Raw Materials has fluctuated over the past 5 years, first declined by 2.68% in 2017, then soared by 49.60% in 2018.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Raw Materials stood at $51.2 million in 2016, then decreased by 2.68% to $49.9 million in 2017, then spiked by 49.60% to $74.6 million in 2018, then decreased by 0.23% to $74.4 million in 2019, then grew by 3.00% to $76.7 million in 2020.